170 related articles for article (PubMed ID: 34923571)
41. Risk of hematological malignancies in the families of patients treated for nodular lymphocyte-predominant Hodgkin lymphoma.
Akhtar S; Rauf MS; Al-Kofide A; Elshenawy MA; Mushtaq AH; Maghfoor I
Hered Cancer Clin Pract; 2021 Feb; 19(1):17. PubMed ID: 33563316
[TBL] [Abstract][Full Text] [Related]
42. Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma.
Borchmann S; Joffe E; Moskowitz CH; Zelenetz AD; Noy A; Portlock CS; Gerecitano JF; Batlevi CL; Caron PC; Drullinsky P; Hamilton A; Hamlin PA; Horwitz SM; Kumar A; Matasar MJ; Moskowitz AJ; Owens CN; Palomba ML; Younes A; Straus DJ
Blood; 2019 May; 133(20):2121-2129. PubMed ID: 30770396
[TBL] [Abstract][Full Text] [Related]
43. Expression of c-FLIP in classic and nodular lymphocyte-predominant Hodgkin lymphoma.
Uherova P; Olson S; Thompson MA; Juskevicius R; Hamilton KS
Appl Immunohistochem Mol Morphol; 2004 Jun; 12(2):105-10. PubMed ID: 15354734
[TBL] [Abstract][Full Text] [Related]
44. High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A retrospective study by the European society for blood and marrow transplantation-lymphoma working party.
Akhtar S; Montoto S; Boumendil A; Finel H; Masszi T; Jindra P; Nemet D; Fuhrmann S; Beguin Y; Castagna L; Ferrara F; Capria S; Malladi R; Moraleda JM; Bloor A; Ghesquières H; Meissner J; Sureda A; Dreger P
Am J Hematol; 2018 Jan; 93(1):40-46. PubMed ID: 28971503
[TBL] [Abstract][Full Text] [Related]
45. Nodular Lymphocyte Predominant Hodgkin Lymphoma With Aberrant Immunophenotype or Variant Histopathology: Insights From Case Series of Three Patients.
Chander G; Dassanayake H; Kaparou M; Ahmed M; Kishore B; Nikolousis E; Kanellopoulos A
Anticancer Res; 2021 Aug; 41(8):4017-4020. PubMed ID: 34281867
[TBL] [Abstract][Full Text] [Related]
46. PD-1, a follicular T-cell marker useful for recognizing nodular lymphocyte-predominant Hodgkin lymphoma.
Nam-Cha SH; Roncador G; Sanchez-Verde L; Montes-Moreno S; Acevedo A; Domínguez-Franjo P; Piris MA
Am J Surg Pathol; 2008 Aug; 32(8):1252-7. PubMed ID: 18594468
[TBL] [Abstract][Full Text] [Related]
47. Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma.
Spinner MA; Varma G; Advani RH
Br J Haematol; 2019 Jan; 184(1):17-29. PubMed ID: 30485408
[TBL] [Abstract][Full Text] [Related]
48. Characterization of variant patterns of nodular lymphocyte predominant hodgkin lymphoma with immunohistologic and clinical correlation.
Fan Z; Natkunam Y; Bair E; Tibshirani R; Warnke RA
Am J Surg Pathol; 2003 Oct; 27(10):1346-56. PubMed ID: 14508396
[TBL] [Abstract][Full Text] [Related]
49. Late recurrence of lymphoid malignancies after initial treatment for Hodgkin lymphoma - A study from the Danish Lymphoma Registry.
Andersen MD; Hamilton-Dutoit S; Modvig L; Vase M; Christiansen I; Christensen JH; Dahl-Sørensen RB; Stoltenberg D; Kamper P; d'Amore F
Br J Haematol; 2022 Jul; 198(1):50-61. PubMed ID: 35396711
[TBL] [Abstract][Full Text] [Related]
50. Diagnostic Utility of Flow Cytometry Analysis of Reactive T Cells in Nodular Lymphocyte-Predominant Hodgkin Lymphoma.
David JA; Huang JZ
Am J Clin Pathol; 2016 Jan; 145(1):107-15. PubMed ID: 26712878
[TBL] [Abstract][Full Text] [Related]
51. Intranodular clusters of activated cells with T follicular helper phenotype in nodular lymphocyte predominant Hodgkin lymphoma: a pilot study of 32 cases from Finland.
Nathwani BN; Vornanen M; Winkelmann R; Kansal R; Doering C; Hartmann S; Hansmann ML
Hum Pathol; 2013 Sep; 44(9):1737-46. PubMed ID: 23684509
[TBL] [Abstract][Full Text] [Related]
52. Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study Group.
Eichenauer DA; Plütschow A; Fuchs M; von Tresckow B; Böll B; Behringer K; Diehl V; Eich HT; Borchmann P; Engert A
J Clin Oncol; 2015 Sep; 33(26):2857-62. PubMed ID: 26240235
[TBL] [Abstract][Full Text] [Related]
53. Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group.
Eichenauer DA; Plütschow A; Schröder L; Fuchs M; Böll B; von Tresckow B; Diehl V; Borchmann P; Engert A
Blood; 2018 Oct; 132(14):1519-1525. PubMed ID: 30064977
[TBL] [Abstract][Full Text] [Related]
54. Highly recurrent mutations of SGK1, DUSP2 and JUNB in nodular lymphocyte predominant Hodgkin lymphoma.
Hartmann S; Schuhmacher B; Rausch T; Fuller L; Döring C; Weniger M; Lollies A; Weiser C; Thurner L; Rengstl B; Brunnberg U; Vornanen M; Pfreundschuh M; Benes V; Küppers R; Newrzela S; Hansmann ML
Leukemia; 2016 Apr; 30(4):844-53. PubMed ID: 26658840
[TBL] [Abstract][Full Text] [Related]
55. Cyclin D1 expression and polysomy in lymphocyte-predominant cells of nodular lymphocyte-predominant Hodgkin lymphoma.
Cho BB; Kelting SM; Gru AA; LeGallo RD; Pramoonjago P; Goldin TA; Heitz CT; Aguilera NS
Ann Diagn Pathol; 2017 Feb; 26():10-15. PubMed ID: 28038705
[TBL] [Abstract][Full Text] [Related]
56. Long-Term Follow-Up of Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma Treated in the HD7 to HD15 Trials: A Report From the German Hodgkin Study Group.
Eichenauer DA; Plütschow A; Fuchs M; Sasse S; Baues C; Böll B; von Tresckow B; Diehl V; Borchmann P; Engert A
J Clin Oncol; 2020 Mar; 38(7):698-705. PubMed ID: 31626571
[TBL] [Abstract][Full Text] [Related]
57. Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma.
Fanale MA; Cheah CY; Rich A; Medeiros LJ; Lai CM; Oki Y; Romaguera JE; Fayad LE; Hagemeister FB; Samaniego F; Rodriguez MA; Neelapu SS; Lee HJ; Nastoupil L; Fowler NH; Turturro F; Westin JR; Wang ML; McLaughlin P; Pinnix CC; Milgrom SA; Dabaja B; Horowitz SB; Younes A
Blood; 2017 Jul; 130(4):472-477. PubMed ID: 28522441
[TBL] [Abstract][Full Text] [Related]
58. A high number of IgG4-positive plasma cells rules out nodular lymphocyte predominant Hodgkin lymphoma.
Kiil K; Bein J; Schuhmacher B; Thurner L; Schneider M; Hansmann ML; Hartmann S
Virchows Arch; 2018 Dec; 473(6):759-764. PubMed ID: 30259184
[TBL] [Abstract][Full Text] [Related]
59. Immunoarchitectural patterns in nodular lymphocyte predominant Hodgkin lymphoma: pathologic and clinical implications.
Gloghini A; Bosco A; Ponzoni M; Spina M; Carbone A
Expert Rev Hematol; 2015 Apr; 8(2):217-23. PubMed ID: 25487651
[TBL] [Abstract][Full Text] [Related]
60. Nodular lymphocyte-predominant Hodgkin lymphoma.
Savage KJ; Mottok A; Fanale M
Semin Hematol; 2016 Jul; 53(3):190-202. PubMed ID: 27496311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
